In the prostate cancer study of 18 patients, 8 were newly diagnosed and 10 had been treated previously, but conventional therapy had failed. All patients had metastases to the bones. After months of therapy, all patients experienced over 30% reduction of their pain scores, and none of the 6 patients who needed morphine before therapy needed to continue it. There was improvement of fatigue in 78% of patients, improvement in urine flow in 83%, improvement in spinal cord compression in 60%, and improvement in urinary bleeding and swelling in 100% (of those that experienced these issues before therapy). The only side effects noted were mild headache or chills during the infusion, which could be prevented by slowing down the infusion.